CTRI/2017/07/008954招募中4 期
A Multi-centric, Double blind, Placebo controlled, Randomized, observational study to evaluate the Efficacy, Safety and tolerability of carica papaya leaf Hydro alcoholic extraction with enriched alkaloids (290 mg) to inhibit Thrombocytopenia induced by Chemotherapy in cancer patients
Katra Phytochem Pvt ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age between 18-75 years
- •2. Has, Grade I to Grade III thrombocytopenia as per CTCAE criteria version 4.0 Platelet count
- •3. Patients undergoing chemotherapy
- •4. Patients with non-hematological malignancies
- •5. Willing and able to sign written informed consent
排除标准
- •1. Present, or history of, acute pro-myelocytic leukemia (APML), immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic-uremic syndrome (HUS)
- •2. Recent history of major surgery (within 2 weeks of study entry)
- •3. Currently taking, or participating in a study involving, platelet substitutes, platelet growth factors, or pharmacologic agents intended to enhance or decrease platelet hemostatic function
- •4. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study
- •5. Current HIV infection or hepatitis B virus or hepatitis C virus infections
- •6. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
- •7. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period
- •8. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test 8.Patients who are deemed unsuitable for the study by the investigator
- •9. Patients with palpable splenomegaly greter than or equal to 16cm below coastal margin
- •10. Female subjects who are pregnant or breastfeeding. Women of childbearing potential are required to have a BHCG serum or urine pregnancy test performed within 7 days prior to first study drug dose. A female of childbearing potential is a sexually mature woman who:
- •1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study
- •participation.
研究者
相似试验
已完成
4 期
Clinical trial for A life saving measure for Dengue patients :Carica Papaya Leaf ExtractCTRI/2018/07/014988Mi Lab LifeSciencesP Limited
已完成
4 期
A life saving measure for Dengue patients :Carica Papaya Leaf ExtractCTRI/2015/05/005806Micro Labs Ltd300
招募中
3 期
Evaluation of Clinical Endpoints of Two Sucralfate suspension, 1g/10mCTRI/2013/04/003538HiTech Pharmacal Co Inc575
招募中
2 期
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesCTRI/2010/091/000151ovartis Healthcare Private Limited244
进行中（未招募）
不适用
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron SyndromeEUCTR2005-004834-42-HUAllergan150